Literature DB >> 23296177

Neuroendocrine tumours in 2012: Insights into signalling pathways could individualize therapy.

Kjell Oberg1.   

Abstract

Neuroendocrine tumours are a heterogeneous group of neoplasms with various clinical presentations, growth rates and responses to available therapies. Studies published in 2012 have provided insights into tumour-cell signalling that will increase our knowledge of tumour biology and molecular genetics, making it possible to personalize patient care.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23296177     DOI： 10.1038/nrendo.2012.250

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


  9 in total

1.  Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.

Authors:  Marianne E Pavel; John D Hainsworth; Eric Baudin; Marc Peeters; Dieter Hörsch; Robert E Winkler; Judith Klimovsky; David Lebwohl; Valentine Jehl; Edward M Wolin; Kjell Öberg; Eric Van Cutsem; James C Yao
Journal:  Lancet       Date:  2011-11-25       Impact factor: 79.321

2.  DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.

Authors:  Yuchen Jiao; Chanjuan Shi; Barish H Edil; Roeland F de Wilde; David S Klimstra; Anirban Maitra; Richard D Schulick; Laura H Tang; Christopher L Wolfgang; Michael A Choti; Victor E Velculescu; Luis A Diaz; Bert Vogelstein; Kenneth W Kinzler; Ralph H Hruban; Nickolas Papadopoulos
Journal:  Science       Date:  2011-01-20       Impact factor: 47.728

3.  Molecular profiling of pancreatic neuroendocrine tumors in sporadic and Von Hippel-Lindau patients.

Authors:  Daniela Speisky; Aurélie Duces; Ivan Bièche; Vinciane Rebours; Pascal Hammel; Alain Sauvanet; Stéphane Richard; Pierre Bedossa; Michel Vidaud; Arnaud Murat; Patricia Niccoli; Jean-Yves Scoazec; Philippe Ruszniewski; Anne Couvelard
Journal:  Clin Cancer Res       Date:  2012-03-29       Impact factor: 12.531

4.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Authors:  Eric Raymond; Laetitia Dahan; Jean-Luc Raoul; Yung-Jue Bang; Ivan Borbath; Catherine Lombard-Bohas; Juan Valle; Peter Metrakos; Denis Smith; Aaron Vinik; Jen-Shi Chen; Dieter Hörsch; Pascal Hammel; Bertram Wiedenmann; Eric Van Cutsem; Shem Patyna; Dongrui Ray Lu; Carolyn Blanckmeister; Richard Chao; Philippe Ruszniewski
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

5.  Everolimus for advanced pancreatic neuroendocrine tumors.

Authors:  James C Yao; Manisha H Shah; Tetsuhide Ito; Catherine Lombard Bohas; Edward M Wolin; Eric Van Cutsem; Timothy J Hobday; Takuji Okusaka; Jaume Capdevila; Elisabeth G E de Vries; Paola Tomassetti; Marianne E Pavel; Sakina Hoosen; Tomas Haas; Jeremie Lincy; David Lebwohl; Kjell Öberg
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

6.  Heterogeneity in signaling pathways of gastroenteropancreatic neuroendocrine tumors: a critical look at notch signaling pathway.

Authors:  He Wang; Yili Chen; Carlos Fernandez-Del Castillo; Omer Yilmaz; Vikram Deshpande
Journal:  Mod Pathol       Date:  2012-08-24       Impact factor: 7.842

7.  The FGFR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy.

Authors:  Stefano Serra; Lei Zheng; Manal Hassan; Alexandria T Phan; Linda J Woodhouse; James C Yao; Shereen Ezzat; Sylvia L Asa
Journal:  Cancer Res       Date:  2012-09-17       Impact factor: 12.701

8.  Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway.

Authors:  Edoardo Missiaglia; Irene Dalai; Stefano Barbi; Stefania Beghelli; Massimo Falconi; Marco della Peruta; Lorenzo Piemonti; Gabriele Capurso; Alessia Di Florio; Gianfranco delle Fave; Paolo Pederzoli; Carlo M Croce; Aldo Scarpa
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544

9.  Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors.

Authors:  Roeland F de Wilde; Christopher M Heaphy; Anirban Maitra; Alan K Meeker; Barish H Edil; Christopher L Wolfgang; Trevor A Ellison; Richard D Schulick; I Quintus Molenaar; Gerlof D Valk; Menno R Vriens; Inne H M Borel Rinkes; G Johan A Offerhaus; Ralph H Hruban; Karen E Matsukuma
Journal:  Mod Pathol       Date:  2012-05-11       Impact factor: 7.842
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.